Kusturica Jasna, Kulo Ćesić Aida, Gušić Edis, Maleškić Sanita, Rakanović-Todić Maida, Šečić Damir
Department of Pharmacology and Toxicology, School of Medicine, University of Sarajevo, Bosnia and Herzegovina.
Department of Health Care, Ministry of Internal Affairs of Canton Sarajevo, Bosnia and Herzegovina.
Med Glas (Zenica). 2017 Aug 1;14(2):176-181. doi: 10.17392/910-17.
Aim In order to increase the database related to the antineoplastic potential of metformin, association between the use of metformin and risk of cancer occurence in patients with diabetes mellitus type 2 (DM2) was investigated. Methods In this cross-sectional study, medical records of patients with DM2 were reviewed for cancer occurence. Data on age, body mass index (BMI), alcohol and nicotine consumption, glucose and HbA1c levels, duration of DM2, medication used in the treatment of DM2 and cancer occurence were collected and analyzed. Unpaired Student's t-test or Mann-Whitney U test were used for comparisons between treatment groups, and logistic regression to asses how well our set of predictor variables predicts occurence of carcinoma. P-value less than 0.05 was considered statistically significant. Results The mean age of 234 included patients was 66.8±11.5 years, and DM2 duration was 7± 6.49 years. Mean glucose value was 8.51±4.17mmol/L, and HbA1c 7.74±1.53. Metformin therapy was prescribed in 190 (81%) patients. Cancer was diagnosed in 16 (6.8%) patients: prostate cancer in eight (3.4%), breast cancer in four (1.7%), rectal cancer in two (0.9%) and cancer of the uterus and cervix in one patient. Age, duration of DM2 and BMI did not contribute significantly to the model, while metformin use was shown to be a significant independent predictor (OR=0.049; 95% CI=0.013-0.181; p=0.001). Conclusion Our findings support the hypothesis that the use of metformin compared to the use of other oral antidiabetic drugs is associated with a lower risk of cancer in patients with DM2.
目的 为了增加与二甲双胍抗肿瘤潜力相关的数据库，研究了2型糖尿病（DM2）患者使用二甲双胍与癌症发生风险之间的关联。方法 在这项横断面研究中，回顾了DM2患者的病历以了解癌症发生情况。收集并分析了有关年龄、体重指数（BMI）、酒精和尼古丁摄入量、血糖和糖化血红蛋白（HbA1c）水平、DM2病程、DM2治疗所用药物以及癌症发生情况的数据。使用非配对学生t检验或曼-惠特尼U检验进行治疗组之间的比较，并使用逻辑回归分析我们的一组预测变量对癌症发生的预测效果。P值小于0.05被认为具有统计学意义。结果 纳入的234例患者的平均年龄为66.8±11.5岁，DM2病程为7±6.49年。平均血糖值为8.51±4.17mmol/L，HbA1c为7.74±1.53。190例（81%）患者接受了二甲双胍治疗。16例（6.8%）患者被诊断患有癌症：8例（3.4%）为前列腺癌，4例（1.7%）为乳腺癌，2例（0.9%）为直肠癌，1例患者为子宫和宫颈癌。年龄、DM2病程和BMI对模型的贡献不显著，而使用二甲双胍被证明是一个显著的独立预测因素（OR=0.049；95%CI=0.013-0.181；p=0.001）。结论我们的研究结果支持以下假设：与使用其他口服降糖药相比，DM2患者使用二甲双胍与较低的癌症风险相关。
